Literature DB >> 19663741

ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs.

Sarah Vautier1, Christine Fernandez.   

Abstract

ABCB1/P-glycoprotein (P-gp) is an ATP-dependant transmembrane efflux protein widely expressed in human organs and plays a protective role against endogenous and exogenous substances. It is involved in drug pharmacokinetics affecting drug absorption, disposition and elimination. At the BBB level, due to its luminal localisation, ABCB1 limits drug transport and is important in central detoxification. Inter-individual variability has been described in ABCB1 expression and functionality. Recent work suggests that variability may play a role in the pathogenesis of neurological diseases. Furthermore, ABCB1 expression and/or functionality may modify drug efficacy or increase central adverse events. This paper reviews ABCB1 implication in the pathophysiology of Parkinson's disease and its role in the cerebral distribution of drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19663741     DOI: 10.1517/17425250903193079

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  17 in total

1.  P-Glycoprotein Transport of Neurotoxic Pesticides.

Authors:  Sarah E Lacher; Kasse Skagen; Joachim Veit; Rachel Dalton; Erica L Woodahl
Journal:  J Pharmacol Exp Ther       Date:  2015-08-13       Impact factor: 4.030

Review 2.  SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers.

Authors:  Marilyn E Morris; Vivian Rodriguez-Cruz; Melanie A Felmlee
Journal:  AAPS J       Date:  2017-06-29       Impact factor: 4.009

Review 3.  Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases.

Authors:  Chaitali Ghosh; Vikram Puvenna; Jorge Gonzalez-Martinez; Damir Janigro; Nicola Marchi
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

4.  Evolutionarily Conserved Roles for Blood-Brain Barrier Xenobiotic Transporters in Endogenous Steroid Partitioning and Behavior.

Authors:  Samantha J Hindle; Roeben N Munji; Elena Dolghih; Garrett Gaskins; Souvinh Orng; Hiroshi Ishimoto; Allison Soung; Michael DeSalvo; Toshihiro Kitamoto; Michael J Keiser; Matthew P Jacobson; Richard Daneman; Roland J Bainton
Journal:  Cell Rep       Date:  2017-10-31       Impact factor: 9.423

Review 5.  Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.

Authors:  Peter Riederer; Thomas Müller
Journal:  J Neural Transm (Vienna)       Date:  2018-03-22       Impact factor: 3.575

Review 6.  PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo.

Authors:  Severin Mairinger; Thomas Erker; Markus Muller; Oliver Langer
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

Review 7.  Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier.

Authors:  David S Miller
Journal:  Trends Pharmacol Sci       Date:  2010-04-24       Impact factor: 14.819

8.  Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat.

Authors:  Sarah E Lacher; Julia N Gremaud; Kasse Skagen; Emily Steed; Rachel Dalton; Kent D Sugden; Fernando Cardozo-Pelaez; Catherine M T Sherwin; Erica L Woodahl
Journal:  J Pharmacol Exp Ther       Date:  2013-12-02       Impact factor: 4.030

Review 9.  Pharmacogenetics of Parkinson's Disease in Clinical Practice.

Authors:  Jean-Christophe Corvol; Werner Poewe
Journal:  Mov Disord Clin Pract       Date:  2016-11-01

10.  First clinical assessment of [18F]MC225, a novel fluorine-18 labelled PET tracer for measuring functional P-glycoprotein at the blood-brain barrier.

Authors:  Jun Toyohara; Muneyuki Sakata; Kenji Ishibashi; Pascalle Mossel; Masamichi Imai; Kei Wagatsuma; Tetsuro Tago; Etsuko Imabayashi; Nicola A Colabufo; Gert Luurtsema; Kenji Ishii
Journal:  Ann Nucl Med       Date:  2021-08-08       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.